Par Pharmaceutical Inc, a developer, manufacturer and marketer of safe, innovative and cost-effective generic pharmaceutical and branded injectable products, and part of Endo International plc (NASDAQ: ENDP), announced on Wednesday that it has started shipping the generic version of Pfizer's Chantix (varenicline), 0.5mg and 1mg tablets.

The company has taken this step subsequent to the final approval from the United States food and Drug Administration for its Abbreviated New Drug Application.

Jon Holden, senior vice president and general manager, Generics at Endo, said, 'This important approval brings the first Chantix generic to the US market. As a reliable, quality supplier, Par is proud to help people during this critical time while also expanding our product portfolio.'